{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:30:08Z","timestamp":1761881408698,"version":"build-2065373602"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Intensiva (English Edition)"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.medine.2022.09.002","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T07:37:56Z","timestamp":1664782676000},"page":"34-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment of severe infections caused by ESBL or carbapenemases-producing Enterobacteriaceae"],"prefix":"10.1016","volume":"47","author":[{"given":"G.","family":"Lombardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.S.","family":"Tanzarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.L.","family":"Cutuli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"De Pascale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medine.2022.09.002_bib0005","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/nyas.12023","article-title":"Proliferation and significance of clinically relevant betalactamases","volume":"1277","author":"Bush","year":"2013","journal-title":"Ann N Y Acad Sci."},{"issue":"1","key":"10.1016\/j.medine.2022.09.002_bib0010","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1128\/CMR.00037-09","article-title":"Three decades of beta-lactamase inhibitors","volume":"23","author":"Drawz","year":"2010","journal-title":"Clin Microbiol Rev."},{"issue":"15","key":"10.1016\/j.medine.2022.09.002_bib0015","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and Outcomes of Infection Among Patients in Intensive Care Units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.medine.2022.09.002_bib0020","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.medine.2022.09.002_bib0025","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jama.2018.12163","article-title":"Effect of piperacillin-tazobactam meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae blood stream infection and ceftriaxone resistance: a randomized clinical trial","volume":"320","author":"Harris","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.medine.2022.09.002_bib0030","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlaa112","article-title":"CON: carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales","volume":"3","author":"Rodr\u00edguez-Ba\u00f1o","year":"2021","journal-title":"JAC-Antimicrob Resist"},{"issue":"3","key":"10.1016\/j.medine.2022.09.002_bib0035","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis."},{"issue":"3","key":"10.1016\/j.medine.2022.09.002_bib0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1473-3099(08)70041-0","article-title":"Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern","volume":"8","author":"Pitout","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"Pt 1","key":"10.1016\/j.medine.2022.09.002_bib0045","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1042\/bj2760269","article-title":"A standard numbering scheme for the class A betalactamases","volume":"276","author":"Ambler","year":"1991","journal-title":"Biochem J."},{"issue":"3","key":"10.1016\/j.medine.2022.09.002_bib0050","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1128\/AAC.01009-09","article-title":"Updated functional classification of betalactamases","volume":"54","author":"Bush","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.medine.2022.09.002_bib0055","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.mib.2006.08.011","article-title":"The CTX-M \u03b2-lactamase pandemic","volume":"9","author":"Canton","year":"2006","journal-title":"Curr Opin Microbiol"},{"issue":"11","key":"10.1016\/j.medine.2022.09.002_bib0060","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/508877","article-title":"Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge","volume":"43","author":"Rodr\u00edguez-Ba\u00f1o","year":"2006","journal-title":"Clin Infect Dis."},{"issue":"suppl 2","key":"10.1016\/j.medine.2022.09.002_bib0065","doi-asserted-by":"crossref","first-page":"391S","DOI":"10.1378\/chest.119.2_suppl.391S","article-title":"Evolution and clinical importance of extended-spectrum \u03b2-lactamases","volume":"119","author":"Rice","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.medine.2022.09.002_bib0070","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1093\/cid\/cix034","article-title":"The use of noncarbapenem-lactams for the treatment of extended-spectrum-lactamase infections","volume":"2017","author":"Tamma","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.09.002_bib0075","first-page":"906","article-title":"Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae","volume":"72","author":"Palacios-Baena","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2022.09.002_bib0080","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1093\/jac\/dky168","article-title":"Clinical effectiveness of carbapenems versus alternative antibiotics for treating ESBL-producing Enterobacteriaceae bacteraemia: A systematic review and meta-analysis","volume":"73","author":"Son","year":"2018","journal-title":"J Antimicrob Chemother"},{"issue":"22","key":"10.1016\/j.medine.2022.09.002_bib0085","first-page":"00086","article-title":"Fast multiplex bacterial PCR of bronchoalveolar lavage for antibiotic stewardship in hospitalised patients with pneumonia at risk of Gram-negative bacterial infection (Flagship II): a multicentre, randomised controlled trial","volume":"S2213-2600","author":"Darie","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.medine.2022.09.002_bib0090","doi-asserted-by":"crossref","first-page":"e3842","DOI":"10.1093\/cid\/ciaa1479","article-title":"Association between minimum inhibitory concentration, beta-lactamase genes and mortality for patients treated with piperacillin\/tazobactam or meropenem from the MERINO study","volume":"73","author":"Henderson","year":"2021","journal-title":"Clin Infect Dis."},{"issue":"2","key":"10.1016\/j.medine.2022.09.002_bib0095","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-040210","article-title":"Piperacillin-tazobactam versus meropenem for treatment of bloodstream infections caused by third-generation cephalosporin-resistant Enterobacteriaceae: a study protocol for a non-inferiority open-label randomised controlled trial (PeterPen)","volume":"11","author":"Bitterman","year":"2021","journal-title":"BMJ Open."},{"issue":"1","key":"10.1016\/j.medine.2022.09.002_bib0100","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/s12879-017-2502-x","article-title":"Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli","volume":"17","author":"Seo","year":"2017","journal-title":"BMC Infect Dis."},{"key":"10.1016\/j.medine.2022.09.002_bib0105","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1128\/AAC.05419-11","article-title":"Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-_-lactamase-producing Klebsiella pneumoniae and Escherichia coli, Antimicrob Agents Chemother","volume":"2012","author":"Chopra","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.medine.2022.09.002_bib0110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.37277","article-title":"Effectiveness of fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract infections: a randomized clinical trial","volume":"5","author":"Sojo-Dorado","year":"2022","journal-title":"JAMA Netw Open."},{"journal-title":"Clin Infect Dis","year":"2022","author":"Tamma","key":"10.1016\/j.medine.2022.09.002_bib0115"},{"issue":"12","key":"10.1016\/j.medine.2022.09.002_bib0120","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis."},{"issue":"8","key":"10.1016\/j.medine.2022.09.002_bib0125","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1080\/14787210.2021.1874918","article-title":"Recent molecules in the treatment of severe infections caused by ESBL-producing bacteria","volume":"19","author":"Russo","year":"2021","journal-title":"Expert Rev Anti Infect Ther."},{"issue":"4","key":"10.1016\/j.medine.2022.09.002_bib0130","doi-asserted-by":"crossref","first-page":"e01989","DOI":"10.1128\/AAC.01989-17","article-title":"A multicenter, randomized, double-blind, phase 2 study of the efficacy and safety of plazomicin compared with levofloxacin in the treatment of complicated urinary tract infection and acute pyelonephritis","volume":"62","author":"Connolly","year":"2018","journal-title":"Antimicrob Agents Chemother."},{"issue":"8","key":"10.1016\/j.medine.2022.09.002_bib0135","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1056\/NEJMoa1801467","article-title":"Once-daily plazomicin for complicated urinary tract infections","volume":"380","author":"Wagenlehner","year":"2019","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.medine.2022.09.002_bib0140","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis."},{"issue":"6","key":"10.1016\/j.medine.2022.09.002_bib0145","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis."},{"issue":"3","key":"10.1016\/j.medine.2022.09.002_bib0150","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis."},{"issue":"12","key":"10.1016\/j.medine.2022.09.002_bib0155","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"9981","key":"10.1016\/j.medine.2022.09.002_bib0160","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet."},{"issue":"10","key":"10.1016\/j.medine.2022.09.002_bib0165","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"C.Clin Infect Dis."},{"issue":"9","key":"10.1016\/j.medine.2022.09.002_bib0170","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1093\/jac\/dkac184","article-title":"Ceftolozane\/tazobactam for hospital-acquired\/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial","volume":"77","author":"Paterson","year":"2022","journal-title":"J Antimicrob Chemother."},{"issue":"1","key":"10.1016\/j.medine.2022.09.002_bib0175","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1093\/jac\/dkw374","article-title":"Efficacy of ceftolozane\/tazobactam against urinary tract and intra-abdominal infections caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae: a pooled analysis of Phase 3 clinical trials","volume":"72","author":"Popejoy","year":"2017","journal-title":"J Antimicrob Chemother."},{"issue":"5","key":"10.1016\/j.medine.2022.09.002_bib0180","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofaa139","article-title":"Ceftolozane\/tazobactam for treatment of severe esbl-producing enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II study)","volume":"7","author":"Bassetti","year":"2020","journal-title":"Open Forum Infect Dis."},{"issue":"1","key":"10.1016\/j.medine.2022.09.002_bib0185","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1186\/s13063-021-05206-8","volume":"22","author":"Stewart","year":"2021","journal-title":"Trials."},{"issue":"Suppl 7","key":"10.1016\/j.medine.2022.09.002_bib0190","doi-asserted-by":"crossref","first-page":"S521","DOI":"10.1093\/cid\/ciz824","article-title":"Epidemiology and Diagnostics of carbapenem resistance in gram-negative bacteria","volume":"69","author":"Nordmann","year":"2019","journal-title":"Clin Infect Dis."},{"issue":"10325","key":"10.1016\/j.medine.2022.09.002_bib0195","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet."},{"issue":"3","key":"10.1016\/j.medine.2022.09.002_bib0200","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1128\/CMR.00001-07","article-title":"Carbapenemases: the versatile beta-lactamases","volume":"20","author":"Queenan","year":"2007","journal-title":"Clin Microbiol Rev."},{"issue":"4","key":"10.1016\/j.medine.2022.09.002_bib0205","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1128\/AAC.45.4.1151-1161.2001","article-title":"Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae","volume":"45","author":"Yigit","year":"2001","journal-title":"Antimicrob Agents Chemother."},{"issue":"3","key":"10.1016\/j.medine.2022.09.002_bib0210","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1093\/jac\/dkm226","article-title":"Class A carbapenemases","volume":"60","author":"Walther-Rasmussen","year":"2007","journal-title":"J Antimicrob Chemother."},{"issue":"7","key":"10.1016\/j.medine.2022.09.002_bib0215","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02000-20","article-title":"Epidemiology of carbapenem resistance determinants identified in meropenem-nonsusceptible enterobacterales collected as part of a global surveillance program, 2012 to 2017","volume":"65","author":"Kazmierczak","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"10.1016\/j.medine.2022.09.002_bib0220","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2174\/138920009787048356","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline","volume":"10","author":"Falagas","year":"2009","journal-title":"Curr Drug Metab."},{"issue":"10","key":"10.1016\/j.medine.2022.09.002_bib0225","doi-asserted-by":"crossref","first-page":"e00797","DOI":"10.1128\/AAC.00797-20","article-title":"Activity of cefiderocol, ceftazidime-avibactam, and eravacycline against carbapenem-resistant Escherichia coli isolates from the united states and international sites in relation to clonal background, resistance genes, coresistance, and region","volume":"64","author":"Johnston","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"issue":"4","key":"10.1016\/j.medine.2022.09.002_bib0230","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijantimicag.2018.07.003","article-title":"In vitro activity of tigecycline and comparators (2014-2016) among key WHO\u2019 priority pathogens\u2019 and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study","volume":"52","author":"Seifert","year":"2018","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.medine.2022.09.002_bib0235","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1186\/cc13858","article-title":"High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria","volume":"18","author":"De Pascale","year":"2014","journal-title":"Crit Care."},{"issue":"9","key":"10.1016\/j.medine.2022.09.002_bib0240","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","article-title":"Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections","volume":"40","author":"Falagas","year":"2005","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.medine.2022.09.002_bib0245","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1586\/eri.12.78","article-title":"Colistin: an update on the antibiotic of the 21st century","volume":"10","author":"Biswas","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"1","key":"10.1016\/j.medine.2022.09.002_bib0250","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1186\/s13054-019-2627-y","article-title":"Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial","volume":"23","author":"Cisneros","year":"2019","journal-title":"Crit Care."},{"issue":"9","key":"10.1016\/j.medine.2022.09.002_bib0255","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis."},{"issue":"2","key":"10.1016\/j.medine.2022.09.002_bib0260","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/cid\/cix783","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant enterobacteriaceae","volume":"66","author":"van Duin","year":"2018","journal-title":"Clin Infect Dis."},{"issue":"10","key":"10.1016\/j.medine.2022.09.002_bib0265","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.cmi.2021.01.020","article-title":"Efficacy of adjunctive nebulized colistin in critically ill patients with nosocomial carbapenem-resistant gram-negative bacterial pneumonia: a multi-centre observational study","volume":"27","author":"Feng","year":"2021","journal-title":"Clin Microbiol Infect."},{"issue":"6","key":"10.1016\/j.medine.2022.09.002_bib0270","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1378\/chest.13-1018","article-title":"Effect of aerosolized colistin as adjunctive treatment on the outcomes of microbiologically documented ventilator-associated pneumonia caused by colistin-only susceptible gram-negative bacteria","volume":"144","author":"Tumbarello","year":"2013","journal-title":"Chest."},{"issue":"9","key":"10.1016\/j.medine.2022.09.002_bib0275","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.cmi.2017.04.011","article-title":"Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases","volume":"23","author":"Rello","year":"2017","journal-title":"Clin Microbiol Infect."},{"issue":"1","key":"10.1016\/j.medine.2022.09.002_bib0280","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/phar.2209","volume":"39","author":"Tsuji","year":"2019","journal-title":"Pharmacotherapy."},{"issue":"1","key":"10.1016\/j.medine.2022.09.002_bib0285","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12941-016-0155-z","article-title":"In vitro potency of amikacin and comparators against E. coli, K. pneumoniae and P. aeruginosa respiratory and blood isolates","volume":"15","author":"Sutherland","year":"2016","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"8","key":"10.1016\/j.medine.2022.09.002_bib0290","doi-asserted-by":"crossref","first-page":"e00313","DOI":"10.1128\/AAC.00313-18","article-title":"In vitro activity of plazomicin against gram-negative and gram-positive isolates collected from U.S. hospitals and comparative activities of aminoglycosides against carbapenem-resistant enterobacteriaceae and isolates carrying carbapenemase genes","volume":"62","author":"Castanheira","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"10.1016\/j.medine.2022.09.002_bib0295","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos","year":"2011","journal-title":"Int J Infect Dis."},{"issue":"11","key":"10.1016\/j.medine.2022.09.002_bib0300","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 Program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis."},{"issue":"8","key":"10.1016\/j.medine.2022.09.002_bib0305","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s10096-021-04197-3","article-title":"Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-\u03b2-lactamase-producing Klebsiella pneumoniae","volume":"40","author":"Maraki","year":"2021","journal-title":"Eur J Clin Microbiol Infect Dis."},{"issue":"3","key":"10.1016\/j.medine.2022.09.002_bib0310","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/jac\/dkz497","article-title":"Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study","volume":"75","author":"Cornely","year":"2020","journal-title":"J Antimicrob Chemother."},{"key":"10.1016\/j.medine.2022.09.002_bib0315","unstructured":"Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03580044."},{"issue":"11","key":"10.1016\/j.medine.2022.09.002_bib0320","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase-producing enterobacterales","volume":"72","author":"Falcone","year":"2021","journal-title":"Clin Infect Dis."},{"issue":"10","key":"10.1016\/j.medine.2022.09.002_bib0325","doi-asserted-by":"crossref","first-page":"6605","DOI":"10.1128\/AAC.01165-15","article-title":"First Report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate","volume":"59","author":"Humphries","year":"2015","journal-title":"Antimicrob Agents Chemother."},{"issue":"9","key":"10.1016\/j.medine.2022.09.002_bib0330","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/cid\/ciab176","article-title":"Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study","volume":"73","author":"Tumbarello","year":"2021","journal-title":"Clin Infect Dis."},{"issue":"8","key":"10.1016\/j.medine.2022.09.002_bib0335","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of Meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA."},{"issue":"4","key":"10.1016\/j.medine.2022.09.002_bib0340","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and Safety of Meropenem-vaborbactam versus best-available therapy in patients with Carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther."},{"issue":"5","key":"10.1016\/j.medine.2022.09.002_bib0345","doi-asserted-by":"crossref","first-page":"e02313","DOI":"10.1128\/AAC.02313-19","article-title":"Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant enterobacteriaceae infections","volume":"64","author":"Ackley","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"issue":"12","key":"10.1016\/j.medine.2022.09.002_bib0350","doi-asserted-by":"crossref","first-page":"e01426","DOI":"10.1128\/AAC.01426-19","article-title":"Searching for the optimal treatment for metallo- and serine-\u03b2-lactamase producing enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam","volume":"63","author":"Biagi","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"issue":"11","key":"10.1016\/j.medine.2022.09.002_bib0355","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study)","volume":"73","author":"Titov","year":"2021","journal-title":"Clin Infect Dis."},{"issue":"Suppl 7","key":"10.1016\/j.medine.2022.09.002_bib0360","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1093\/cid\/ciz828","article-title":"Pharmacokinetic and pharmacodynamic profiles of cefiderocol, a novel siderophore cephalosporin","volume":"69","author":"Katsube","year":"2019","journal-title":"Clin Infect Dis."},{"author":"Dimitrova","key":"10.1016\/j.medine.2022.09.002_bib0365"},{"issue":"2","key":"10.1016\/j.medine.2022.09.002_bib0370","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis."},{"issue":"Suppl 7","key":"10.1016\/j.medine.2022.09.002_bib0375","doi-asserted-by":"crossref","first-page":"S544","DOI":"10.1093\/cid\/ciz827","article-title":"In vitro activity of cefiderocol against a broad range of clinically important gram-negative bacteria","volume":"69","author":"Yamano","year":"2019","journal-title":"Clin Infect Dis."},{"issue":"5","key":"10.1016\/j.medine.2022.09.002_bib0380","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.mib.2010.09.004","article-title":"Combating evolution with intelligent design: the neoglycoside ACHN-490","volume":"13","author":"Armstrong","year":"2010","journal-title":"Curr Opin Microbiol"},{"issue":"3","key":"10.1016\/j.medine.2022.09.002_bib0385","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s40265-019-1054-3","article-title":"Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections","volume":"79","author":"Eljaaly","year":"2019","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.medine.2022.09.002_bib0390","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1056\/NEJMc1807634","article-title":"Plazomicin for infections caused by carbapenem-resistant enterobacteriaceae","volume":"380","author":"McKinnell","year":"2019","journal-title":"N Engl J Med."},{"key":"10.1016\/j.medine.2022.09.002_bib0395","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2217\/fmb-2019-0135","article-title":"Eravacycline: a new treatment option for complicated intra-abdominal infections in the age of multidrug resistance","volume":"14","author":"Solomkin","year":"2019","journal-title":"Future Microbiol."},{"author":"Francisco","key":"10.1016\/j.medine.2022.09.002_bib0400"}],"container-title":["Medicina Intensiva (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572722002259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572722002259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:36:22Z","timestamp":1761878182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173572722002259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S2173572722002259"],"URL":"https:\/\/doi.org\/10.1016\/j.medine.2022.09.002","relation":{},"ISSN":["2173-5727"],"issn-type":[{"type":"print","value":"2173-5727"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of severe infections caused by ESBL or carbapenemases-producing Enterobacteriaceae","name":"articletitle","label":"Article Title"},{"value":"Medicina Intensiva (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medine.2022.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}